In a landmark moment for diagnostic innovation in India, HORIBA India, in collaboration with Voice of Healthcare (VOH), hosted a high-impact event to unveil its latest breakthrough in immunoassay technology – the YUMIZEN M300 Immunoassay Analyzer. The gathering brought together a select group of eminent clinicians and healthcare leaders, including endocrinologists, gynecologists, pathologists, IVF specialists, pediatricians, neonatologists, internal medicine experts, and laboratory professionals, for an evening that seamlessly combined scientific insight with technological advancement.
The event commenced with a welcome address by Dr. Rajeev Gautam, (Senior Corporate Officer – HORIBA, Ltd. Japan and President- HORIBA India) who extended his greetings to the esteemed speakers, guests, and partners. Dr. Gautam set the tone for the evening by emphasizing the shared vision of Horiba – “to bridge the gap between advanced diagnostics and practical clinical utility, particularly in the rapidly evolving field of immunology.”
The evening opened with a keynote by Dr. A.K. Harith, Prof- Dept of Biochemistry, Amrita School of Medicine and Amrita Hospital, Faridabad who traced the evolution of immunoassays from rudimentary enzymology and ELISA methods to today’s sophisticated CLIA platforms and pointof-care devices. Dr. Harith remarked, “Now we can practically analyze anything under the sun using immunoassays.” He urged clinicians and laboratories to break the “vicious cycle” where new biomarkers are neither requested by clinicians nor offered by labs, stressing that “when a lab result doesn’t match the patient, speak to the lab—not just repeat the test elsewhere.”
Following the keynote, Panel 1: Navigating Diagnostic Diversity—Harmonization Strategies in Immunology & Hormonal Testing, moderated by Dr. Ajay Gupta (Dr Lal PathLabs), featured Dr. Prabhat Ranjan Sinha (Aakash Healthcare), Dr. Sanjay Wazir (Motherhood Hospital), and Dr. Ruchi Kapoor (Redcliffe Labs). Dr. Prabhat emphasized the importance of judicious test ordering, cautioning that “blanket testing of all hormone levels in all patients is not justified; it should be directed by clinical presentation and disease prevalence.” Dr. Sanjay Wazir highlighted the urgency in neonatal settings: “Delaying diagnosis by even 15 days in congenital hypothyroidism could mean losing 15 IQ points.” Dr. Ruchi Kapoor addressed technical variability, noting that “there are multiple sources of variation—platforms, reagents, calibrators, sample collection timing—and deciding between integrated systems or standalone CLIA depends on sample load and lab requirements.”
The next session, Panel 2: Relevance of Immunology Markers and Diagnostic Techniques in Fertility & Reproductive Medicine, moderated by Dr. Sohini Sen Gupta (Healthians Labs), included Dr. K.D. Nayar (Akanksha IVF Centre), Dr. Rupali Bassi (Apollo Hospital, New Delhi), Dr. Arpita Roy Dam (Tata 1mg), Dr. Vishu Bhasin (Dr Bhasin’s Lab), and Dr. Tushar Sehgal (AIIMS, New Delhi). The discussion focused on the role of immunoassays in fertility, recurrent pregnancy loss, ovarian reserve, and reproductive diagnostics. Dr. Nayar stated, “AMH is central to assessing ovarian reserve and guiding infertility care.” Dr. Bassi highlighted Indian applicability, noting that “while the international AMH cutoff for PCOS is 4.5 ng/mL, local studies suggest cutoffs closer to 7 ng/mL, reflecting ethnic and age variability”. Dr. Roy Dam spoke on tumor marker usage, cautioning, “These markers should not be used as routine screening alone—they need clinical and radiological correlation.” Dr. Bhasin emphasized standardization and clinician confidence: “Testing must be stratified by guidelines; reporting protocols should be uniform so busy clinicians can interpret quickly.” Dr. Sehgal reminded the audience that “free hormone assays (free T3, free T4, free testosterone) yield more physiologically accurate results in states where binding proteins are altered, even if they come at higher cost.” Moderator Dr. Sen Gupta concluded by reinforcing that lab testing and clinical context must evolve together, not in isolation
The highlight of the evening was the grand launch of the YUMIZEN M300 Immunoassay Analyzer, a milestone marking HORIBA India’s entry into the field of Immunology. Designed to empower laboratories, clinicians, and healthcare institutions nationwide, the analyzer offers enhanced precision, simplicity, and speed. The launch featured a digital countdown, creating anticipation for the breakthrough poised to redefine diagnostics and patient care. The product was jointly unveiled by Dr. Rajeev Gautam and Dr. Ashok Ratan, formally introduced amid applause, ceremonial ribbon-cutting, and enthusiastic responses from the attendees.